A semi-thorough DD on $ETTX - 03-03-2021
Ticker: ETTX Company Name: Entasis Therapeutics Holdings Inc. Trading @ 3.11 CNN Money Analysts Link: https://money.cnn.com/quote/forecast/forecast.html?symb=ETTX Price Target: $5 - $9 News: Benzinga: https://www.benzinga.com/pressreleases/21/01/g19317814/entasis-therapeutics-announces-sulbactam-durlobactam-expanded-access-program-for-patients-in-the-u From BioPharmCatalyst & Company Website: https://www.biopharmcatalyst.com/company/ETTX https://www.entasistx.com/pipeline SULBACTAM-DURLOBACTAM (ETX2514SUL) - A multidrug resistant Acinetobacter infections — Phase 3 - Durlobactam (DUR; previously designated ETX2514) is our novel, broad-spectrum and potent inhibitor of Class A, C, and D β-lactamases. Sulbactam (SUL) is a β-lactam antibiotic with activity against Acinetobacter baumannii; however, β-lactamase-mediated resistance to sulbactam is now widespread rendering it generally ineffective. In preclinical studies, durlobactam inhibits the β-lactamases commonly found in...